Evidence mapPaperPMID 36101515Full record

Trial reportMolecular nutrition & food research2022

Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial.

Juergen Grafeneder, Ulla Derhaschnig, Farsad Eskandary, Nina Buchtele, Nadine Sus, Jan Frank, Bernd Jilma, Christian Schoergenhofer

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Molecular nutrition & food research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Juergen GrafenederDepartment of Emergency Medicine, Medical University of Vienna, Vienna, 1090, Austria.ORCID 0000-0002-3639-0106
Ulla DerhaschnigDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Farsad EskandaryDivision of Nephrology, Department of Medicine III, Medical University of Vienna, Vienna, 1090, Austria.
Nina BuchteleDepartment of Medicine I, Medical University of Vienna, Vienna, 1090, Austria.
Nadine SusDepartment of Food Biofunctionality (140b), Institute of Nutritional Sciences, University of Hohenheim, Stuttgart, Germany.
Jan FrankDepartment of Food Biofunctionality (140b), Institute of Nutritional Sciences, University of Hohenheim, Stuttgart, Germany.
Bernd JilmaDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Christian SchoergenhoferDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Medical University of Vienna · ATUniversity of Hohenheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

scopePreclinical models have demonstrated the anti-inflammatory and lipid-lowering effects of curcumin. Innovative formulations have been developed to overcome the poor bioavailability of native curcumin. The study hypothesizes that the bioavailability of micellar curcumin is superior to native curcumin and investigates the potential anti-inflammatory and proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration lowering effects. METHODS AND

resultsIn this double-blind, randomized, crossover trial, 15 healthy volunteers receive micellar or native curcumin (105 mg day

conclusionMicellar curcumin demonstrates an improved oral bioavailability but does not show anti-inflammatory effects in this model. Potential effects on PCSK9 concentrations warrant further investigation.

Indexed as

CurcuminProprotein Convertase 9Anti-Inflammatory AgentsBiomarkersCross-Over StudiesHealthy VolunteersHumansInflammationInterleukin-6MicellesAnti-Inflammatory AgentsBiomarkersCurcuminInterleukin-6MicellesPCSK9 protein, humanProprotein Convertase 9curcumininflammationinterleukin-6lipopolysaccharidePCSK9pharmacokineticsTNF-α

Identifiers

PMID36101515
PMCPMC9787856
OpenAlexW4295759023

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.